Shin Jie Yong, MSc (Res)
1 min readJan 12, 2022

--

First, based on the biodistribution studies, the LNP+mRNA vaccine rarely enters other tissues besides the injection site and liver. As follows, the spike protein expression beyond the injection site would be minimal. The expressed spike protein on the cell surface also doesn’t last very long, probably only long enough until dendritic cells have processed the spike protein and activate the adaptive immune system. So, by the time killer T-cells arrive, the cells hardly express the spike protein anymore.

I’m aware that this is just theory based on studies showing that mRNA vaccine-induced protein expression lasts for about a week only (I cited these studies, animal studies actually, in a previous article linked below). And the adaptive immune system takes about two weeks to activate.

https://medium.com/microbial-instincts/concerns-of-lipid-nanoparticle-carrying-mrna-vaccine-into-the-brain-what-to-make-of-it-42b1a98dae27?sk=dcc637826b31b81cb2e4d0728fd3a066

About the aspiration, it’s possible that the vaccine injected into a vein could cause harm. Scientists have theorized that this could be the probable cause of mRNA vaccine-related myocarditis and DNA vaccine-related blood clots. This is also based on an animal study that found that intravenous injection of mRNA vaccine caused myocarditis while intramuscular injection didn’t. I’ve also written about this here if you are interested:

https://medium.com/microbial-instincts/heart-inflammation-from-mrna-vaccine-probable-causes-and-precautions-72a2745635b?sk=1822dc5f2dd387cc74664d485506ec05

The links are friend linked (no paywall), which automatically becomes the original link once the webpage loads. I hope that helps a bit but just let me know if anything is unclear.

--

--

Shin Jie Yong, MSc (Res)
Shin Jie Yong, MSc (Res)

Written by Shin Jie Yong, MSc (Res)

Named Stanford's world top 1% scientists | Medium's boost nominator | National athlete | Ghostwriter | Get my Substack: https://theinfectedneuron.substack.com/

Responses (1)